ROC-101 exhibits favorable pharmacokinetics for once-daily dosing Data support the potential therapeutic efficacy of ROC-101; justify further development via a Phase 2, proof-of-concept trial in patients with PAH or ILD-PH slated to begin Q4 2025 […]
